Graft-versus-host Disease, Low Donor T-cell Chimerism, Poor Graft Function
Conditions
Keywords
Mesenchymal stem cells, Graft-versus-host disease, Poor graft function, Chimerism, Hematopoietic cell transplantation recipients, Low donor T-cell chimerism
Brief summary
The present project aims at investigating the role of MSC for the treatment of patients with Part 1: Steroid-refractory grade II-IV acute GVHD. Part 2: Poor graft function (PGF) Part 3: Low or falling donor T-cell chimerism after allogeneic HCT. This is a multicenter phase II study examining the feasibility and efficacy of this approach.
Detailed description
Part 1: complete recruitment Part 2: complete recruitment Part 3: recruiting
Interventions
BIOLOGICALMesenchymal stem cells
Mesenchymal Stem Cell infusion
Sponsors
KU Leuven
Maastricht University Medical Center
Ziekenhuis Netwerk Antwerpen (ZNA)
University Hospital, Antwerp
University Hospital, Ghent
AZ-VUB
AZ Sint-Jan AV
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
University Hospital of Mont-Godinne
Jolimont Hospital Haine Saint Paul
Queen Fabiola Children's University Hospital
University of Liege
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
Patient eligibility criteria 1. Male or female of any age. 2. Previous allogeneic transplantation (related or unrelated donor, any degree of HLA matching) or autologous transplantation (for part 2 only) of HSC at any time before. 3. Any source of HSC (marrow, PBSC, cord blood) and any conditioning regimen. 4. Informed consent given by donor or his/her guardian if of minor age. 5. Additional criteria for each part of the protocol: Part 1: MSC for steroid-refractory grade II-IV acute GVHD 1. Allogeneic transplantation. 2. Grade II-IV acute GVHD (see appendix A for acute GVHD grading) de novo or following DLI. 3. Acute GVHD refractory to mPDN 2 mg/kg/day or equivalent, defined as * progression of GVHD on day 3 after initiation of steroids * no improvement of GVHD on day 7 after initiation of steroids * absence of complete resolution of acute GVHD on day 14 after initiation of steroids * relapse of acute GVHD during or after steroid taper. 4. Ongoing therapy with Ciclosporine or Tacrolimus at therapeutic doses. 5. Patient may have received previously any other form of treatment for acute GVHD, but no new treatment started within 1 month of study entry. Part 2: MSC for poor graft function (PGF) 1. Allogeneic or autologous transplantation. 2. Cytopenia in 2 or 3 lineages: * Hb \< 8.0 g/dL and reticulocytes \< 1%, with or without transfusion * Plt \< 20,000/µL without transfusion * Neutrophils \< 500/µL, without G-CSF administration OR severe cytopenia in 1 lineage: * RBC transfusion dependent (if autologous transplantation; despite EPO administration if allogeneic transplantation) * Plt transfusion dependent * Neutrophils \< 500/µL despite G-CSF administration 3. Cytopenia duration ≥ 2 weeks beyond day 28 after autologous HCT, or day 42 (day 60 for cord blood transplantation) after allogeneic HCT. 4. Cytopenia is not related to CMV or other infection, myelosuppressive/toxic drugs, renal failure, peripheral cell destruction or other identifiable cause. 5. In case of HLA-identical related donor and full donor chimerism, patient can only be included if a boost of donor CD34+ cells has been unsuccessful or is not feasible. Part 3: MSC + DLI for poor donor T-cell chimerism 1. Nonmyeloablative allogeneic transplantation. 2. Donor T-cell chimerism \< 50% for at least 2 consecutive weeks beyond day 21 after HCT OR * 20% decrease in donor T-cell chimerism with the second value \< 50%. MSC donor inclusion criteria 1. Related to the recipient (sibling, parent or child) or unrelated. 2. Male or female. 3. Age \> 16 yrs (no age limit if same as HSC donor). 4. No HLA matching required. 5. Fulfills generally accepted criteria for allogeneic HSC donation. 6. Informed consent given by donor or his/her guardian if of minor age.
Exclusion criteria
Patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Arm 1. Efficacy of MSC infusion as treatment for steroid-resistant grade II - IV acute GVHD. | 30 days |
| Arm 2. Efficacy of MSC infusion as treatment for poor graft function | 180 days |
| Arm 3. Efficacy of MSC infusion followed by donor lymphocyte infusion for preventing graft rejection in patients with low or failing donor T-cell chimerism after allogeneic HCT | 180 days |
Secondary
| Measure | Time frame |
|---|---|
| Toxicity of MSC infusion | 180 days |
Countries
Belgium, Netherlands
Contacts
Primary ContactYves Beguin, MD, PhD
Backup ContactFrederic Baron, MD, PhD
Outcome results
None listed